Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and ability of panobinostat to re-activate
HIV transcription in latently infected CD4+ T-cells among HIV-infected patients on stable
antiretroviral therapy
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Aarhus
Collaborators:
Aarhus University Hospital Massachusetts General Hospital Monash University Novartis University of Sydney